Inebilizumab treatment in Japanese patients with IgG4-related disease: A subgroup analysis of a randomized, double-blind, placebo-controlled, phase 3 trial (MITIGATE)
Modern Rheumatology · 31.08.2026 · 36 (5) · 801-808
DOI: 10.1093/mr/roag020 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Modern Rheumatology, online erschienen am 06.03.2026. Verfasst von Yoshiya Tanaka und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Targeted Therapeutics, First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Immunoglobulin G4-Related Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Tanabe Pharma Corporation.
Abstract (Originalsprache)
Objectives
This subgroup analysis of the MITIGATE study aimed to evaluate whether the efficacy and safety of inebilizumab in Japanese patients with IgG4-related disease are consistent with those observed in the overall trial population.
Methods
MITIGATE was a randomized, double-blind, placebo-controlled, phase 3 study conducted in 22 countries, and this subgroup analysis included the Japanese patients enrolled in that trial.
Results
In total, 27 Japanese patients (inebilizumab, N = 20; placebo, N = 7) were included in this subgroup analysis. The organs most frequently affected were the submandibular gland (66.7%), lacrimal gland (59.3%), and pancreas (51.9%). Despite the discontinuation of glucocorticoids within 8 weeks of study initiation, there were no adjudication committee-determined flares requiring treatment in the inebilizumab group. Flares were observed in four patients (57.1%) in the placebo group, with a median time to the first flare of 246.0 days. Inebilizumab reduced the annualized flare rate, increased flare-free complete remission, and lowered glucocorticoid use. Safety profiles were similar between treatment groups; most treatment-emergent adverse events were non-serious.
Conclusions
Inebilizumab reduced flare risk and glucocorticoid exposure, and it was well tolerated in Japanese patients with IgG4-related disease, which is consistent with the overall MITIGATE results.
Trial registration
NCT04540497.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Targeted Therapeutics, First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
- Center for RA and Autoimmune Diseases, Nagahama City Hospital, Nagahama, Japan.
- Medical Affairs Department, Tanabe Pharma Corporation, Tokyo, Japan.
- Medical Affairs Department, Tanabe Pharma Corporation, Osaka, Japan.
- Clinical Science Department, Tanabe Pharma Corporation, Tokyo, Japan.
- Department of Internal Medicine, Kansai Medical University Kori Hospital, Neyagawa, Japan.
ORCID-Profile: Yoshiya Tanaka
Förderung
- Tanabe Pharma Corporation
Zitieren
APA
Tanaka, Y., Umehara, H., Sato, H., Uchima, K., Kawai, K., & Okazaki, K. (2026). Inebilizumab treatment in Japanese patients with IgG4-related disease: A subgroup analysis of a randomized, double-blind, placebo-controlled, phase 3 trial (MITIGATE). Modern Rheumatology, 36(5), 801-808. https://doi.org/10.1093/mr/roag020
Vancouver
Tanaka Y, Umehara H, Sato H, Uchima K, Kawai K, Okazaki K. Inebilizumab treatment in Japanese patients with IgG4-related disease: A subgroup analysis of a randomized, double-blind, placebo-controlled, phase 3 trial (MITIGATE). Modern Rheumatology. 2026;36(5):801-808. doi:10.1093/mr/roag020
BibTeX
@article{Tanaka2026,
author = {Tanaka, Yoshiya and Umehara, Hisanori and Sato, Hirokazu and Uchima, Kosuke and Kawai, Kouji and Okazaki, Kazuichi},
title = {Inebilizumab treatment in Japanese patients with IgG4-related disease: A subgroup analysis of a randomized, double-blind, placebo-controlled, phase 3 trial (MITIGATE)},
journal = {Modern Rheumatology},
year = {2026},
volume = {36},
number = {5},
pages = {801--808},
doi = {10.1093/mr/roag020}
}
EUVIMED